Artelo Biosciences, Inc. (ARTL) stock
ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.68−0.02 (-1.18%)
Close on Nov 17, 2026Market cap $1.13MP/E –Yield –
Artelo Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Artelo Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.82M, down 37.0% year over year. For fiscal 2025 it was $5.42M, down 9.5% from the year before. The highest annual figure on record is $5.99M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.42M | -9.5% |
| FY2024 | Dec 31, 2024 | $5.99M | +5.2% |
| FY2023 | Dec 31, 2023 | $5.70M | +100.6% |
| FY2021 | Aug 31, 2021 | $2.84M | +47.9% |
| FY2020 | Aug 31, 2020 | $1.92M | +75.7% |
| FY2019 | Aug 31, 2019 | $1.09M | -12.6% |
| FY2018 | Aug 31, 2018 | $1.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $876.00K | -53.2% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $773.00K | -44.1% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $893.00K | -63.9% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $1.28M | +292.3% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $1.87M | +11.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $1.38M | -8.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $2.48M | +16.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $325.00K | -79.5% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $1.69M | +124.1% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $1.51M | +22.0% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $2.12M | +245.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $1.59M | +66.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $752.00K | +13.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $1.24M | +107.6% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $615.46K | +126.2% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $951.20K | +267.7% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $663.36K | -8.0% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $595.00K | -10.8% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $272.08K | +16.4% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $258.68K | +40.4% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $721.31K | +47.2% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $666.94K | +262.4% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $233.77K | -29.7% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $184.20K | -22.2% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $489.98K | -24.3% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $184.04K | +456.4% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $332.47K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $236.85K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $647.47K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $33.08K | – |
See a number that looks wrong?